<DOC>
	<DOCNO>NCT00596596</DOCNO>
	<brief_summary>The purpose study determine whether prucalopride safe effective patient chronic idiopathic constipation . Hypothesis : At dos administer prucalopride give daily 4 week safe well tolerated patient chronic idiopathic constipation .</brief_summary>
	<brief_title>Trial Evaluate Efficacy Safety R093877 Patients With Chronic Idiopathic Constipation</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomize , parallel group , multicentre , Phase II , dose comparison trial , 313 subject , history chronic idiopathic constipation enrol . The trial conduct three phase : 1. 4-week drug-free run-in phase , 2. 4-week double-blind ( DB ) phase subject treat R093877 ( 0.5 mg , 1 mg , 2 mg , 4 mg capsule ) match placebo daily , prior breakfast , 3. 4-week drug-free run-out phase ( RO ) . To qualify run-in phase ( Visit 1 , Week 1 ) subject experience , least 3 month , 2 less spontaneous , bowel movement ( SBM ) /week occurrence lumpy ( scyballae ) and/or hard stool , sensation incomplete evacuation least quarter stool , strain defecation least quarter time .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Male nonpregnant female outsubjects 18 70 year age . Documented history constipation . The subject report 2 less SCBM/week occurrence one follow least 3 month selection visit : lumpy ( scyballae ) and/or hard stool least quarter stool ; sensation incomplete evacuation follow least quarter stool ; strain defecation least quarter time . These criterion applicable spontaneous , complete bowel movement , i.e. , precede within period 24 hour intake laxative agent . Normal inhibition pattern external anal sphincter straining , i.e. , relaxation m. puborectalis distal displacement rectal canal ( digital examination and/or electromyographic and/or manometric evidence acceptable ) . The subject 's constipation functional , i.e. , idiopathic . Written informed consent , sign subject and/or legal guardian investigator . Subject available followup trial period , determine protocol . Subjects constipation thought druginduced . Subject suffer types/causes constipation idiopathic constipation , i.e. , presence secondary cause constipation include : Endocrine disorder Metabolic disorder Neurologic disorder include : Irritable bowel syndrome . Subjects congenital megacolon/megarectum diagnosis pseudoobstruction . History previous abdominal surgery ( exclude hysterectomy , surgery Meckel 's diverticle , appendectomy , cholecystectomy , inguinal hernia repair , splenectomy , nephrectomy , fundoplication ) think primary cause constipation . Known suspect organic disorder large bowel ( i.e. , obstruction , carcinoma , inflammatory bowel disease ) . Subjects active proctological condition think responsible constipation . Subjects ECG abnormality include : 2nd 3rd degree AV block ; prolong QTc interval ( &gt; 460 msec ) ; bradycardia ( &lt; equal 60 bpm ) . Subjects receive concomitant medication could cause QT prolongation Subjects potassiumwasting diuretic . Subjects know illness condition : severe cardiovascular lung disease , neurologic psychiatric disorder ( include active alcohol drug abuse ) , cancer , AIDS , gastrointestinal endocrine disorder . Subjects impaired renal function Subjects serum amylase , AST ( SGOT ) , ALT ( SGPT ) concentration &gt; 2 time normal limit . Subjects clinically significant abnormality hematology , urinalysis blood chemistry . Females childbearing potential without adequate contraceptive protection trial . Oral Females pregnant lactating . Subjects received investigational drug 30 day precede runin phase trial . Subjects unable unwilling return require followup visit . Subjects whose reliability physical state hinder adequate participation clinical trial . Subjects polyps discover screen colonoscopy untreated ( i.e. , polypectomy ) . Subjects polyps screen colonoscopy treat polypectomy allow enter trial 4week healing period . Any subject polyp ( ) document contain invasive carcinoma ( Duke 's B great ) exclude trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Constipation</keyword>
	<keyword>prucalopride</keyword>
</DOC>